17,261 trials
Intraocular Pressure
Primary: Change in Mean Diurnal IOP at Visit 6 (Day 28) — -7.829; -8.295; -8.952; -8.894 mm Hg
Impetigo · Secondarily Infected Traumatic Lesions
Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants
Mild Cognitive Impairment
Primary: 15-Item Word List Delayed Recall — -0.3; -0.5 units on a scale - change from baseline — p=<.05
Secondarily Infected Traumatic Lesions (SITL) · Impetigo
Primary: TD1414 Serum Concentration by Timepoint — 624.3; 864.1; 1195.7; 888.4 pg/mL
HIV-2 Infection
Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) — 1200 dose in mg/m^2
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Cervical Cancer · Precancerous Condition
Primary: Safety and Toxicity — 0; 0; 0 Participants
Nausea · Vomiting
Primary: Efficacy for the Prevention/Rescue of Radiation-induced Nausea and Vomiting. — 21; 4; 2; 0 Participants
Rhinitis · Allergic · Seasonal
Primary: Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I — -3.80; -7.15; -7.05; -7.93 units on a scale — p=<0.001
Epilepsy · Dravet Syndrome
Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 0; 1 Participants
Depressive Symptoms · Anxiety · Cancer
Primary: GRID-HAM-D-17 -- Structured Interview Guide for the Hamilton Depression Scale. — 22.32; 14.8; 6.5; 6.95 units on a scale
Adenocarcinoma of the Prostate
Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months
Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 4; 3 Participants